Mumumutelu // Shutterstock Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are used to treat obesity, Type 2 diabetes, and more. These...
Vous n'êtes pas connecté
Maroc - WN.COM - Science - 14/Jan 03:25
Mumumutelu // Shutterstock Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are used to treat obesity, Type 2 diabetes, and more. These medications, while helpful for these conditions, could indirectly cause fluid or electrolyte imbalances. LMNT shares what to watch for and how to strategize with electrolytes. Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications — sold under the blockbuster brand names Ozempic, Wegovy, Mounjaro, and more — have dominated headlines in recent years. These marvels of modern medicine help treat the chronic conditions of obesity and Type 2 diabetes. They do this by mimicking the natural GLP-1 gut hormone, which has beneficial effects on glucose...
Mumumutelu // Shutterstock Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are used to treat obesity, Type 2 diabetes, and more. These...
WEDNESDAY, Jan. 14, 2026 -- More than one-quarter of adults aged 25 to 64 years from 99 countries are eligible to receive a glucagon-like peptide-1...
Audience: Health Care Professional, Consumer January 13, 2026 FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With...
Audience: Health Care Professional, Consumer January 13, 2026 FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With...
KK Stock // Shutterstock Glucagon-like peptide-1 (GLP-1) medications, such as Wegovy (semaglutide), have helped many people lose weight. Until...
KK Stock // Shutterstock Glucagon-like peptide-1 (GLP-1) medications, such as Wegovy (semaglutide), have helped many people lose weight. Until...
Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, like the popular weight-loss jabs Wegovy and Ozempic, have proven to be immensely effective....
Glucagon-like peptide-1 (GLP-1) receptor agonist drugs, like the popular weight-loss jabs Wegovy and Ozempic, have proven to be immensely effective....
MONDAY, Jan. 12, 2026 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal cancer (CRC)...
MONDAY, Jan. 12, 2026 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal cancer (CRC)...